In conclusion, the PACMEL phase II trial found that adding the MEK inhibitor trametinib to paclitaxel chemotherapy significantly improved PFS and ORR in patients with BRAF-wt melanoma, but did not impact OS. This evidence concerns the gene BRAF and melanoma.